Cannabis Law Report

MAY 19, 2022

This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.

Therapy 52

Therapy Treatment Clinical Trials Access 52

Veriheal

JUNE 29, 2021

In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine. Today there are 41 states that have enacted some form of a Right to Try or RTT laws. A Push by Patients. Patients Are Not In This Alone.

Therapy 55

Therapy DEA Patients Clinical Trials 55

Cannabis Law Report

FEBRUARY 24, 2022

Canada recently amended its Controlled Drugs and Substances Act (CDSA) to allow for psilocybin and MDMA therapy in limited circumstances. Subsection 56(1) of the CDSA will exempt medical providers from enforcement of the CDSA when providing psilocybin and MDMA treatment to patients suffering serious or terminal health conditions.

Therapy 52

Therapy Access Clinical Trials Treatment 52

Cannabis Law Report

AUGUST 18, 2022

The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Veriheal

JULY 18, 2023

Notably, the grant program will target three prevalent and often debilitating conditions in military personnel: PTSD, traumatic brain injury (TBI) , and chronic traumatic encephalopathy (CTE). This could foster a pool of experts well-versed in applying psychedelic-assisted therapy.

Treatment 98

Treatment Clinical Trials Research and Development Legislation 98

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Veriheal

JUNE 7, 2021

Always consult a physician before attempting alternative therapies. It turns out that this blissful drug, MDMA, has the potential to be used effectively as a treatment for certain conditions- some of which are in urgent need of effective medical assistance. . What is MDMA? Consuming Therapeutically and Recreationally.

Therapy 82

Therapy Treatment Conditions Clinical Trials 82

Cannabis Law Report

DECEMBER 14, 2021

IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The primary endpoint of our Phase 1 clinical trial was to test and demonstrate safety and tolerability.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

MMJ Recs

MAY 9, 2024

Many veterans struggle with various physical and psychological conditions resulting from their service. These professionals can provide valuable insights into whether medical cannabis is a suitable option based on the veteran’s medical history, current conditions, and treatment goals.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

MAY 19, 2022

After a psilocybin treatment,(it’s like) you’re still in your car, in traffic, but you have the windows up; the air conditioning is on and it’s quiet. Before January, people could only access psychedelic-assisted psychotherapy through clinical trials or medical exemptions. It’s just you and the music.”

Therapy 52

Therapy Patients Treatment Clinical Trials 52

Cannabis Law Report

JULY 9, 2021

The state of the law on psychedelic substances is in flux. The use of psychedelic substances to treat mental illness and physical disorders is known as “psychedelic therapy.” Psychedelic therapy is not a fringe phenomenon. Some of the most promising substances, and the law applicable to each, are outlined below: Psilocybin.

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

OCTOBER 22, 2021

(TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce that following discussions with the U.K. Small Pharma initiated a clinical program into DMT-assisted therapy in February 2021. About Small Pharma. Small Pharma Inc.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. No approved TNF inhibitor has ever been dosed orally.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Veriheal

MARCH 20, 2023

Alternative medicine is becoming more widely acknowledged and practiced than ever before, opening the door for therapies like psychedelics to enter the world of mainstream healthcare. Psilocybin therapy is both studied and used by highly legitimate medical establishments. Ned Lamont signed a bill (HB 5506) to fund psychedelic therapy.

Clinical Trials 98

Clinical Trials Therapy Decriminalization Treatment 98

The Cannigma

FEBRUARY 1, 2023

Patients are often left to their own devices when looking into cannabis and cancer, given the lack of clinical evidence, and stigma surrounding the use of the plant as medicine. Individuals who use cannabis-based medications often want to cure their cancer, not just reduce the symptoms that come with the condition. The answer: Maybe!

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

MAY 28, 2022

Husch Blackwell is the the first Am Law 100 firm to offer counsel for companies in the emerging psychedelic industry. Natasha Sumner, Kimberly Chew and Karen Luong are attorneys in Husch Blackwell LLP’s virtual office, The Link, and lead the firm’s Psychedelics & Emerging Therapies practice. Here’s the introduction.

Research and Development 52

Research and Development Therapy Clinical Trials Legalization 52

Cannabis Law Report

DECEMBER 5, 2021

Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once certain financial milestones are met. The safety and efficacy of MDMA-assisted therapy is currently under investigation.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Canna Law Blog

NOVEMBER 6, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Research was permitted in the mid-20th century, until the law stepped in. Instead, qualifying evidence may come from adequate and well-controlled clinical trials.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

JUNE 24, 2022

The leader of the New Jersey Senate filed a bill on Thursday that would legalize the possession, home cultivation and gifting of psilocybin mushrooms for adults 21 and older—with provisions that give adults even more freedoms for the psychedelic than are afforded under the state’s current marijuana laws. Full story at. Full story at.

Clinical Trials 52

Clinical Trials Legalization Research and Development Therapy 52

Cannabis Law Report

MAY 31, 2022

Two approaches apply to commercial operations—the traditional medical path and the emerging non-medical state-regulated path, while the other two paths are better seen as non-commercial—underground therapy and religious use. There are also illicit sales of psychedelic drugs separate from any therapeutic or ceremonial use.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. MEDIA CONTACT .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

JANUARY 9, 2019

“I would never have thought to get into the medical cannabis industry, it always just seemed like an excuse for people to get high,” he told Cannabis Law Report. Then I saw someone with Stage 4 breast cancer end up in remission from cannabis-based therapy, someone else with skin cancer; kid after kid with seizures all being treated.

Therapy 85

Therapy Clinical Trials Treatment Medicine 85

Cannabis Law Report

OCTOBER 19, 2021

Unlike other therapies, MYMD-1 has been shown to selectively block TNF-? In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation. a driver of chronic inflammation. No approved TNF inhibitor has ever been dosed orally.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

SEPTEMBER 9, 2021

MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes. Supera-CBD is being developed to address anxiety, chronic pain, addiction, and seizures, and is on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

Cannabis Law Report

AUGUST 25, 2021

Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Cannabis Law Report

JANUARY 12, 2022

The sale will accelerate the development of Gb Sciences’ proprietary Parkinson’s disease and COVID-related Cytokine-Release Syndrome therapies. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.”

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

OCTOBER 5, 2021

Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions. The Independent Expert Panel was established to undertake a systematic literature review of the roles of MDMA and psilocybin for the treatment of mental health conditions. 30 September 2021.

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

Cannabis Law Report

MAY 10, 2022

Of the 248,000 scripts approved for Australians since inception of national medicinal cannabis scheme in 2016, many related to conditions for which the drug has limited evidence of efficacy, a new University of Sydney study shows. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

OCTOBER 20, 2021

Tory MP Crispin Blunt urged the PM to review the law to allow more research into the drug’s therapeutic qualities. Mr Blunt said it had “exciting potential” for the treatment of mental health conditions such as depression, trauma and addiction. CRISPIN BLUNT’S QUESTION AT. Source: [link].

Supply Chain 52

Supply Chain Clinical Trials Therapy Treatment 52

Cannabis Law Report

OCTOBER 9, 2021

A coalition of Pennsylvania lawmakers introduced a bill this week that’s meant to promote research into the therapeutic potential of psilocybin mushrooms for mental health conditions such as post-traumatic stress disorder (PTSD)—the latest example of how the psychedelics reform movement is gaining momentum. Led by Rep.

Therapy 52

Therapy Clinical Trials Treatment Legislation 52

Cannabis Law Report

AUGUST 30, 2021

It’s considered a breakthrough therapy,” Dr McTaggart said. “With COVID-19 right now, I think there’s never been a better time to start looking for therapies for mental health.” . “In America the USDA [United States Department of Agriculture] has fast tracked psilocybin treatment.

Clinical Trials 105

Clinical Trials Collective Therapy Treatment 105

Cannabis Law Report

SEPTEMBER 1, 2021

The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. His background is a mix of cognitive psychology, clinical psychology and computer science. Diversified Drug Development.

Research and Development 102

Research and Development Therapy Clinical Trials Pharmaceutical 102

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52